We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Alpha Lipoic Acid vs Omega-3: Omega-3 has the stronger overall evidence (9 vs 7/10); they're alternatives for metabolic health — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Omega-3 wins 3 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Likely helps
8 of 10 studies with measurable effects showed benefit.
Top outcomes
Verdict
Probably helps
10 of 15 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (1)
Outcomes where both Alpha Lipoic Acid and Omega-3 have evidence — compare verdict strength side-by-side.
300-600mg
On empty stomach for best absorption, 30-60 minutes before meals
R-Alpha Lipoic Acid (R-ALA) — the natural form
2-3g combined EPA+DHA daily (a typical label dose, not the dose used in the cited trials, which gave 1 g or 3.25 g of omega-3 a day, or 1 to 4 g of fish oil a day without stating its EPA+DHA content)
With meals containing fat
Triglyceride form fish oil
4-12 weeks
4-8 weeks
2-4 weeks
4-8 weeks
2-4 weeks
Immediate
4-12 weeks
Effects of Oral Alpha-Lipoic Acid Treatment on Diabetic Polyneuropathy: A Meta-Analysis and Systematic Review
Nutrients (2023) · Meta analysis · n=1242
ALA treatment produced favorable results for TSS (a dose-related trend was observed), NDS, and the global satisfaction score.
Effects of selected dietary supplements on migraine prophylaxis: A systematic review and dose-response meta-analysis of randomized controlled trials
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2025) · Meta analysis
Twenty-two trials were included in the systematic review and meta-analysis.
The Effect of Dietary Supplements on Male Infertility in Terms of Pregnancy, Live Birth, and Sperm Parameters: A Systematic Review and Meta-Analysis
Nutrients (2025) · Meta analysis
Systematic review and meta-analysis of 50 placebo-controlled trials of dietary supplements lasting at least 12 weeks in infertile men.
Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer
The New England journal of medicine (2019) · Rct · n=25871
During a median follow-up of 5.3 years, a major cardiovascular event occurred in 386 participants in the n-3 group and in 419 in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.80 to 1.06; P=0.24).
Omega-3 fatty acids for intermittent claudication
The Cochrane database of systematic reviews (2024) · Meta analysis · n=1830
Omega-3 compared with a control may have little to no effect on ankle-brachial index (MD -0.02, 95% CI -0.08 to 0.04; 3 studies, 168 participants; very low-certainty evidence).
A systematic review and meta-analysis of the omega-3 fatty acids effects on brain-derived neurotrophic factor (BDNF)
Nutritional neuroscience (2024) · Meta analysis · n=587
12 RCTs with 587 subjects: omega-3 supplementation increased serum BDNF versus placebo (SMD 0.72, 95% CI 0.28 to 1.15), with high heterogeneity (I2 = 84.39%).
The points come from the SYDNEY 2 trial (PMID 17065669), which gave 181 people with diabetic polyneuropathy 600, 1,200 or 1,800 mg once daily or placebo for 5 weeks. All three doses beat placebo on the Total Symptom Score, with about the same size of effect: responder rates (a 50% or greater fall) were 62%, 50% and 56% against 26% on placebo, and effectiveness here is the responder rate above placebo. Nausea, vomiting and vertigo rose with dose, and the authors judged 600 mg once daily the best balance of benefit and risk. Doses below 600 mg were not tested. A 6-month trial of 1,200 mg a day in 200 patients (PMID 32370731) found benefit with mild nausea in 6 patients and no withdrawals, which is the basis for the 1,200 mg ceiling. A meta-analysis of 10 trials reported a dose-related trend in symptom scores (PMID 37630823), which the one head-to-head dose trial did not show.
The points are the dose bands of a meta-analysis of 10 randomised trials with 1,426 adults (PMID 37028202): EPA-rich products at 1 to under 2 g of EPA a day reduced depression severity (SMD -0.43), while 2 g a day or more did not (SMD -0.20, not significant), so the 2 g point is plotted as no effect. Doses are grams of EPA, not EPA plus DHA. The Cochrane review of 33 placebo-controlled trials found a small to modest effect, unlikely to be clinically meaningful and rated very low certainty, with no difference in remission or response (PMID 34817851). No trial compared doses directly.
AI-estimated from published studies. Interpret as directional guidance.
Omega-3 has a higher evidence score (9/10 vs 7/10) and wins in 3 of 3 categories.
For metabolic health, Alpha Lipoic Acid has a higher relevance score (90 vs 75).
No documented interaction was found in the data searched. This does not establish that this exact combination is safe.
Berberine, inositol, magnesium vs the cinnamon/chromium hype — and the med-interaction warning.
The honest tier list — proven staples vs situational vs mostly marketing. The hub the other guides feed into.
On Ozempic/Wegovy/Mounjaro? What actually helps — muscle preservation, GI relief, nutrient gaps (no upsell).
Which supplements clash with blood thinners, thyroid meds, antibiotics & more — and what to do.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.